Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Edward L. Giovannucci, D.Sc., M.D.

Co-Author

This page shows the publications co-authored by Edward Giovannucci and Lorelei Mucci.
Connection Strength

13.170
  1. Is Vasectomy a Cause of Prostate Cancer? J Natl Cancer Inst. 2020 01 01; 112(1):5-6.
    View in: PubMed
    Score: 0.889
  2. Reply to D.C. Sokal et al. J Clin Oncol. 2015 Feb 20; 33(6):670-1.
    View in: PubMed
    Score: 0.631
  3. Prenatal and Perinatal Factors and Risk of Cancer in Middle and Older Adulthood among Men. Cancer Epidemiol Biomarkers Prev. 2021 Jul 16.
    View in: PubMed
    Score: 0.247
  4. Association of Prediagnostic Blood Metabolomics with Prostate Cancer Defined by ERG or PTEN Molecular Subtypes. Cancer Epidemiol Biomarkers Prev. 2021 May; 30(5):1000-1008.
    View in: PubMed
    Score: 0.241
  5. Gene Expression Pathways in Prostate Tissue Associated with Vigorous Physical Activity in Prostate Cancer. Cancer Epidemiol Biomarkers Prev. 2021 04; 30(4):751-756.
    View in: PubMed
    Score: 0.239
  6. Insulinemic and Inflammatory Dietary Patterns and Risk of Prostate Cancer. Eur Urol. 2021 03; 79(3):405-412.
    View in: PubMed
    Score: 0.238
  7. The association of diabetes with risk of prostate cancer defined by clinical and molecular features. Br J Cancer. 2020 08; 123(4):657-665.
    View in: PubMed
    Score: 0.229
  8. Height as a mediator of sex differences in cancer risk. Ann Oncol. 2020 05; 31(5):634-640.
    View in: PubMed
    Score: 0.226
  9. A Metabolomics Analysis of Adiposity and Advanced Prostate Cancer Risk in the Health Professionals Follow-Up Study. Metabolites. 2020 Mar 10; 10(3).
    View in: PubMed
    Score: 0.225
  10. Statin Use Is Associated with Lower Risk of PTEN-Null and Lethal Prostate Cancer. Clin Cancer Res. 2020 03 01; 26(5):1086-1093.
    View in: PubMed
    Score: 0.220
  11. Body fat distribution on computed tomography imaging and prostate cancer risk and mortality in the AGES-Reykjavik study. Cancer. 2019 08 15; 125(16):2877-2885.
    View in: PubMed
    Score: 0.214
  12. Circulating 25-hydroxyvitamin D, vitamin D binding protein and risk of advanced and lethal prostate cancer. Int J Cancer. 2019 05 15; 144(10):2401-2407.
    View in: PubMed
    Score: 0.206
  13. A Prospective Study of the Association between Physical Activity and Risk of Prostate Cancer Defined by Clinical Features and TMPRSS2:ERG. Eur Urol. 2019 07; 76(1):33-40.
    View in: PubMed
    Score: 0.204
  14. Family History of Breast or Prostate Cancer and Prostate Cancer Risk. Clin Cancer Res. 2018 12 01; 24(23):5910-5917.
    View in: PubMed
    Score: 0.202
  15. Height, Obesity, and the Risk of TMPRSS2:ERG-Defined Prostate Cancer. Cancer Epidemiol Biomarkers Prev. 2018 02; 27(2):193-200.
    View in: PubMed
    Score: 0.192
  16. Midlife metabolic factors and prostate cancer risk in later life. Int J Cancer. 2018 03 15; 142(6):1166-1173.
    View in: PubMed
    Score: 0.192
  17. Gene expression profiling of prostate tissue identifies chromatin regulation as a potential link between obesity and lethal prostate cancer. Cancer. 2017 Nov 01; 123(21):4130-4138.
    View in: PubMed
    Score: 0.187
  18. The role of tumor metabolism as a driver of prostate cancer progression and lethal disease: results from a nested case-control study. Cancer Metab. 2016; 4:22.
    View in: PubMed
    Score: 0.180
  19. Vascular morphology differentiates prostate cancer mortality risk among men with higher Gleason grade. Cancer Causes Control. 2016 08; 27(8):1043-7.
    View in: PubMed
    Score: 0.174
  20. Reply to Cédric Annweiler, Pierre Bigot, and Spyridon N. Karras' Letter to the Editor re: Jennifer R. Rider, Kathryn M. Wilson, Jennifer A. Sinnott, Rachel S. Kelly, Lorelei A. Muccia, Edward L. Giovannucci. Ejaculation Frequency and Risk of Prostate Cancer: Updated Results with an Additional Decade of Follow-up. Eur Urol 2016;70:974-82. Eur Urol. 2017 01; 71(1):e18.
    View in: PubMed
    Score: 0.174
  21. Reply to Herney Andrés García-Perdomo and Ramiro Manzano Nunez's Letter to the Editor Re: Jennifer R. Rider, Kathryn M. Wilson, Jennifer M. Sinnott, Rachel S. Kelly, Lorelei A. Mucci, Edward L. Giovannucci. Ejaculation Frequency and Risk of Prostate Cancer: Updated Results with an Additional Decade of Follow-up. Eur Urol 2016;70:974-82: Looking Deeper: P-hacking and Some Other Bias. Eur Urol. 2016 12; 70(6):e156-e157.
    View in: PubMed
    Score: 0.172
  22. Metabolomic Biomarkers of Prostate Cancer: Prediction, Diagnosis, Progression, Prognosis, and Recurrence. Cancer Epidemiol Biomarkers Prev. 2016 06; 25(6):887-906.
    View in: PubMed
    Score: 0.171
  23. Ejaculation Frequency and Risk of Prostate Cancer: Updated Results with an Additional Decade of Follow-up. Eur Urol. 2016 12; 70(6):974-982.
    View in: PubMed
    Score: 0.171
  24. Dietary lycopene intake and risk of prostate cancer defined by ERG protein expression. Am J Clin Nutr. 2016 Mar; 103(3):851-60.
    View in: PubMed
    Score: 0.169
  25. Body size across the life course and prostate cancer in the Health Professionals Follow-up Study. Int J Cancer. 2016 Feb 15; 138(4):853-65.
    View in: PubMed
    Score: 0.165
  26. Evaluating a 4-marker signature of aggressive prostate cancer using time-dependent AUC. Prostate. 2015 Dec; 75(16):1926-33.
    View in: PubMed
    Score: 0.165
  27. Physical Activity and Prostate Tumor Vessel Morphology: Data from the Health Professionals Follow-up Study. Cancer Prev Res (Phila). 2015 Oct; 8(10):962-967.
    View in: PubMed
    Score: 0.164
  28. No Association of ApoE Genotype with Risk of Prostate Cancer: A Nested Case-Control Study. Cancer Epidemiol Biomarkers Prev. 2015 Oct; 24(10):1632-4.
    View in: PubMed
    Score: 0.163
  29. Asthma and risk of lethal prostate cancer in the Health Professionals Follow-Up Study. Int J Cancer. 2015 Aug 15; 137(4):949-58.
    View in: PubMed
    Score: 0.159
  30. Calcium and phosphorus intake and prostate cancer risk: a 24-y follow-up study. Am J Clin Nutr. 2015 Jan; 101(1):173-83.
    View in: PubMed
    Score: 0.156
  31. Vasectomy and risk of aggressive prostate cancer: a 24-year follow-up study. J Clin Oncol. 2014 Sep 20; 32(27):3033-8.
    View in: PubMed
    Score: 0.154
  32. Androgen receptor CAG repeat polymorphism and risk of TMPRSS2:ERG-positive prostate cancer. Cancer Epidemiol Biomarkers Prev. 2014 Oct; 23(10):2027-31.
    View in: PubMed
    Score: 0.151
  33. RE: Plasma phospholipid fatty acids and prostate cancer risk in the SELECT trial. J Natl Cancer Inst. 2014 Apr; 106(4):dju018.
    View in: PubMed
    Score: 0.149
  34. SPINK1 protein expression and prostate cancer progression. Clin Cancer Res. 2014 Sep 15; 20(18):4904-11.
    View in: PubMed
    Score: 0.149
  35. Dietary lycopene, angiogenesis, and prostate cancer: a prospective study in the prostate-specific antigen era. J Natl Cancer Inst. 2014 Feb; 106(2):djt430.
    View in: PubMed
    Score: 0.147
  36. Modification of the association between obesity and lethal prostate cancer by TMPRSS2:ERG. J Natl Cancer Inst. 2013 Dec 18; 105(24):1881-90.
    View in: PubMed
    Score: 0.146
  37. Total antioxidant intake in relation to prostate cancer incidence in the Health Professionals Follow-Up Study. Int J Cancer. 2014 Mar 01; 134(5):1156-65.
    View in: PubMed
    Score: 0.145
  38. Prostate-specific membrane antigen protein expression in tumor tissue and risk of lethal prostate cancer. Cancer Epidemiol Biomarkers Prev. 2013 Dec; 22(12):2354-63.
    View in: PubMed
    Score: 0.144
  39. Protein expression of PTEN, insulin-like growth factor I receptor (IGF-IR), and lethal prostate cancer: a prospective study. Cancer Epidemiol Biomarkers Prev. 2013 Nov; 22(11):1984-93.
    View in: PubMed
    Score: 0.143
  40. A single nucleotide polymorphism in inflammatory gene RNASEL predicts outcome after radiation therapy for localized prostate cancer. Clin Cancer Res. 2013 Mar 15; 19(6):1612-9.
    View in: PubMed
    Score: 0.138
  41. Prediagnostic circulating sex hormones are not associated with mortality for men with prostate cancer. Eur Urol. 2014 Apr; 65(4):683-9.
    View in: PubMed
    Score: 0.137
  42. Common genetic variation of the calcium-sensing receptor and lethal prostate cancer risk. Cancer Epidemiol Biomarkers Prev. 2013 Jan; 22(1):118-26.
    View in: PubMed
    Score: 0.135
  43. The TMPRSS2:ERG rearrangement, ERG expression, and prostate cancer outcomes: a cohort study and meta-analysis. Cancer Epidemiol Biomarkers Prev. 2012 Sep; 21(9):1497-509.
    View in: PubMed
    Score: 0.132
  44. Seasonal variation in expression of markers in the vitamin D pathway in prostate tissue. Cancer Causes Control. 2012 Aug; 23(8):1359-66.
    View in: PubMed
    Score: 0.132
  45. Lifestyle and dietary factors in the prevention of lethal prostate cancer. Asian J Androl. 2012 May; 14(3):365-74.
    View in: PubMed
    Score: 0.130
  46. Vitamin D-related genetic variation, plasma vitamin D, and risk of lethal prostate cancer: a prospective nested case-control study. J Natl Cancer Inst. 2012 May 02; 104(9):690-9.
    View in: PubMed
    Score: 0.130
  47. Milk and dairy consumption among men with prostate cancer and risk of metastases and prostate cancer death. Cancer Epidemiol Biomarkers Prev. 2012 Mar; 21(3):428-36.
    View in: PubMed
    Score: 0.129
  48. Dietary acrylamide and risk of prostate cancer. Int J Cancer. 2012 Jul 15; 131(2):479-87.
    View in: PubMed
    Score: 0.125
  49. Coffee consumption and prostate cancer risk and progression in the Health Professionals Follow-up Study. J Natl Cancer Inst. 2011 Jun 08; 103(11):876-84.
    View in: PubMed
    Score: 0.122
  50. Genetic variation in the toll-like receptor 4 and prostate cancer incidence and mortality. Prostate. 2012 Feb 01; 72(2):209-16.
    View in: PubMed
    Score: 0.122
  51. Vitamin D receptor protein expression in tumor tissue and prostate cancer progression. J Clin Oncol. 2011 Jun 10; 29(17):2378-85.
    View in: PubMed
    Score: 0.122
  52. Prediagnostic plasma vitamin D metabolites and mortality among patients with prostate cancer. PLoS One. 2011 Apr 06; 6(4):e18625.
    View in: PubMed
    Score: 0.121
  53. Dietary zinc and prostate cancer survival in a Swedish cohort. Am J Clin Nutr. 2011 Mar; 93(3):586-93.
    View in: PubMed
    Score: 0.119
  54. Genetic variation in RNASEL associated with prostate cancer risk and progression. Carcinogenesis. 2010 Sep; 31(9):1597-603.
    View in: PubMed
    Score: 0.115
  55. Immunohistochemical expression of BRCA1 and lethal prostate cancer. Cancer Res. 2010 Apr 15; 70(8):3136-9.
    View in: PubMed
    Score: 0.113
  56. Prospective study of prostate tumor angiogenesis and cancer-specific mortality in the health professionals follow-up study. J Clin Oncol. 2009 Nov 20; 27(33):5627-33.
    View in: PubMed
    Score: 0.110
  57. Prospective study of Trichomonas vaginalis infection and prostate cancer incidence and mortality: Physicians' Health Study. J Natl Cancer Inst. 2009 Oct 21; 101(20):1406-11.
    View in: PubMed
    Score: 0.109
  58. Circulating prediagnostic interleukin-6 and C-reactive protein and prostate cancer incidence and mortality. Int J Cancer. 2009 Jun 01; 124(11):2683-9.
    View in: PubMed
    Score: 0.107
  59. Gleason score and lethal prostate cancer: does 3 + 4 = 4 + 3? J Clin Oncol. 2009 Jul 20; 27(21):3459-64.
    View in: PubMed
    Score: 0.106
  60. Publisher Correction: Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction. Nat Genet. 2021 Mar; 53(3):413.
    View in: PubMed
    Score: 0.060
  61. Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction. Nat Genet. 2021 01; 53(1):65-75.
    View in: PubMed
    Score: 0.060
  62. Metabolomic Signatures of Long-term Coffee Consumption and Risk of Type 2 Diabetes in Women. Diabetes Care. 2020 10; 43(10):2588-2596.
    View in: PubMed
    Score: 0.058
  63. Baldness and Risk of Prostate Cancer in the Health Professionals Follow-up Study. Cancer Epidemiol Biomarkers Prev. 2020 06; 29(6):1229-1236.
    View in: PubMed
    Score: 0.057
  64. Family history of prostate cancer and the incidence of ERG- and phosphatase and tensin homolog-defined prostate cancer. Int J Cancer. 2020 05 15; 146(10):2694-2702.
    View in: PubMed
    Score: 0.054
  65. Identification of Plasma Lipid Metabolites Associated with Nut Consumption in US Men and Women. J Nutr. 2019 07 01; 149(7):1215-1221.
    View in: PubMed
    Score: 0.054
  66. Alcohol Intake and Risk of Lethal Prostate Cancer in the Health Professionals Follow-Up Study. J Clin Oncol. 2019 06 10; 37(17):1499-1511.
    View in: PubMed
    Score: 0.053
  67. The associations of anthropometric, behavioural and sociodemographic factors with circulating concentrations of IGF-I, IGF-II, IGFBP-1, IGFBP-2 and IGFBP-3 in a pooled analysis of 16,024 men from 22 studies. Int J Cancer. 2019 12 15; 145(12):3244-3256.
    View in: PubMed
    Score: 0.053
  68. Intratumoral Sterol-27-Hydroxylase (CYP27A1) Expression in Relation to Cholesterol Synthesis and Vitamin D Signaling and Its Association with Lethal Prostate Cancer. Cancer Epidemiol Biomarkers Prev. 2019 06; 28(6):1052-1058.
    View in: PubMed
    Score: 0.053
  69. Coffee consumption and plasma biomarkers of metabolic and inflammatory pathways in US health professionals. Am J Clin Nutr. 2019 03 01; 109(3):635-647.
    View in: PubMed
    Score: 0.052
  70. Guideline-Based Physical Activity and Survival Among US Men With Nonmetastatic Prostate Cancer. Am J Epidemiol. 2019 03 01; 188(3):579-586.
    View in: PubMed
    Score: 0.052
  71. Pre-diagnostic 25-hydroxyvitamin D levels and survival in cancer patients. Cancer Causes Control. 2019 Apr; 30(4):333-342.
    View in: PubMed
    Score: 0.052
  72. Author Correction: Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci. Nat Genet. 2019 02; 51(2):363.
    View in: PubMed
    Score: 0.052
  73. Expression of IGF/insulin receptor in prostate cancer tissue and progression to lethal disease. Carcinogenesis. 2018 12 31; 39(12):1431-1437.
    View in: PubMed
    Score: 0.052
  74. Aspirin Use and Lethal Prostate Cancer in the Health Professionals Follow-up Study. Eur Urol Oncol. 2019 03; 2(2):126-134.
    View in: PubMed
    Score: 0.050
  75. Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci. Nat Genet. 2018 07; 50(7):928-936.
    View in: PubMed
    Score: 0.050
  76. Fine-mapping of prostate cancer susceptibility loci in a large meta-analysis identifies candidate causal variants. Nat Commun. 2018 06 11; 9(1):2256.
    View in: PubMed
    Score: 0.050
  77. Differential Gene Expression in Prostate Tissue According to Ejaculation Frequency. Eur Urol. 2018 11; 74(5):545-548.
    View in: PubMed
    Score: 0.050
  78. Current or recent smoking is associated with more variable telomere length in prostate stromal cells and prostate cancer cells. Prostate. 2018 02; 78(3):233-238.
    View in: PubMed
    Score: 0.048
  79. MYC Overexpression at the Protein and mRNA Level and Cancer Outcomes among Men Treated with Radical Prostatectomy for Prostate Cancer. Cancer Epidemiol Biomarkers Prev. 2018 02; 27(2):201-207.
    View in: PubMed
    Score: 0.048
  80. Cholesterol uptake and regulation in high-grade and lethal prostate cancers. Carcinogenesis. 2017 08 01; 38(8):806-811.
    View in: PubMed
    Score: 0.047
  81. Weight change, obesity and risk of prostate cancer progression among men with clinically localized prostate cancer. Int J Cancer. 2017 09 01; 141(5):933-944.
    View in: PubMed
    Score: 0.047
  82. The ABC model of prostate cancer: A conceptual framework for the design and interpretation of prognostic studies. Cancer. 2017 05 01; 123(9):1490-1496.
    View in: PubMed
    Score: 0.045
  83. Familial Risk and Heritability of Colorectal Cancer in the Nordic Twin Study of Cancer. Clin Gastroenterol Hepatol. 2017 Aug; 15(8):1256-1264.
    View in: PubMed
    Score: 0.045
  84. Circulating Antioxidant Levels and Risk of Prostate Cancer by TMPRSS2:ERG. Prostate. 2017 May; 77(6):647-653.
    View in: PubMed
    Score: 0.045
  85. Early Life Residence, Fish Consumption, and Risk of Breast Cancer. Cancer Epidemiol Biomarkers Prev. 2017 03; 26(3):346-354.
    View in: PubMed
    Score: 0.044
  86. Meat, Fish, Poultry, and Egg Intake at Diagnosis and Risk of Prostate Cancer Progression. Cancer Prev Res (Phila). 2016 Dec; 9(12):933-941.
    View in: PubMed
    Score: 0.044
  87. Cholesterol Metabolism and Prostate Cancer Lethality. Cancer Res. 2016 08 15; 76(16):4785-90.
    View in: PubMed
    Score: 0.043
  88. Calcium-Sensing Receptor Tumor Expression and Lethal Prostate Cancer Progression. J Clin Endocrinol Metab. 2016 06; 101(6):2520-7.
    View in: PubMed
    Score: 0.043
  89. Pre-diagnostic circulating sex hormone levels and risk of prostate cancer by ERG tumour protein expression. Br J Cancer. 2016 Apr 12; 114(8):939-44.
    View in: PubMed
    Score: 0.043
  90. Risk of prostate cancer-specific death in men with baseline metabolic aberrations treated with androgen deprivation therapy for biochemical recurrence. BJU Int. 2016 Dec; 118(6):919-926.
    View in: PubMed
    Score: 0.043
  91. Common variation in BRCA1 may have a role in progression to lethal prostate cancer after radiation treatment. Prostate Cancer Prostatic Dis. 2016 06; 19(2):197-201.
    View in: PubMed
    Score: 0.043
  92. A Prospective Investigation of PTEN Loss and ERG Expression in Lethal Prostate Cancer. J Natl Cancer Inst. 2016 Feb; 108(2).
    View in: PubMed
    Score: 0.042
  93. Stress-Related Signaling Pathways in Lethal and Nonlethal Prostate Cancer. Clin Cancer Res. 2016 Feb 01; 22(3):765-772.
    View in: PubMed
    Score: 0.042
  94. ABO blood group alleles and prostate cancer risk: Results from the breast and prostate cancer cohort consortium (BPC3). Prostate. 2015 Nov; 75(15):1677-81.
    View in: PubMed
    Score: 0.041
  95. Statin use and risk of prostate cancer: Results from the Southern Community Cohort Study. Prostate. 2015 Sep; 75(13):1384-93.
    View in: PubMed
    Score: 0.040
  96. Prediagnostic Obesity and Physical Inactivity Are Associated with Shorter Telomere Length in Prostate Stromal Cells. Cancer Prev Res (Phila). 2015 Aug; 8(8):737-42.
    View in: PubMed
    Score: 0.040
  97. Tumor expression of adiponectin receptor 2 and lethal prostate cancer. Carcinogenesis. 2015 Jun; 36(6):639-47.
    View in: PubMed
    Score: 0.040
  98. Circulating vitamin D, vitamin D-related genetic variation, and risk of fatal prostate cancer in the National Cancer Institute Breast and Prostate Cancer Cohort Consortium. Cancer. 2015 Jun 15; 121(12):1949-56.
    View in: PubMed
    Score: 0.040
  99. The TMPRSS2:ERG fusion and response to androgen deprivation therapy for prostate cancer. Prostate. 2015 Jun 15; 75(9):897-906.
    View in: PubMed
    Score: 0.040
  100. A meta-analysis of 87,040 individuals identifies 23 new susceptibility loci for prostate cancer. Nat Genet. 2014 Oct; 46(10):1103-9.
    View in: PubMed
    Score: 0.038
  101. 5a-Reductase inhibitors and risk of high-grade or lethal prostate cancer. JAMA Intern Med. 2014 Aug; 174(8):1301-7.
    View in: PubMed
    Score: 0.038
  102. Prostate cancer (PCa) risk variants and risk of fatal PCa in the National Cancer Institute Breast and Prostate Cancer Cohort Consortium. Eur Urol. 2014 Jun; 65(6):1069-75.
    View in: PubMed
    Score: 0.037
  103. Gleason grade progression is uncommon. Cancer Res. 2013 Aug 15; 73(16):5163-8.
    View in: PubMed
    Score: 0.036
  104. Prostate cancer cell telomere length variability and stromal cell telomere length as prognostic markers for metastasis and death. Cancer Discov. 2013 Oct; 3(10):1130-41.
    View in: PubMed
    Score: 0.035
  105. Whole milk intake is associated with prostate cancer-specific mortality among U.S. male physicians. J Nutr. 2013 Feb; 143(2):189-96.
    View in: PubMed
    Score: 0.034
  106. Dietary fatty acid intake and prostate cancer survival in Örebro County, Sweden. Am J Epidemiol. 2012 Aug 01; 176(3):240-52.
    View in: PubMed
    Score: 0.033
  107. Association of metabolic syndrome with reduced survival among men receiving androgen deprivation therapy for nonmetastatic prostate cancer. J Clin Oncol. 2012 Feb 10; 30(5_suppl):56.
    View in: PubMed
    Score: 0.032
  108. Common polymorphisms in the adiponectin and its receptor genes, adiponectin levels and the risk of prostate cancer. Cancer Epidemiol Biomarkers Prev. 2011 Dec; 20(12):2618-27.
    View in: PubMed
    Score: 0.031
  109. a-Methylacyl-CoA racemase expression and lethal prostate cancer in the Physicians' Health Study and Health Professionals Follow-up Study. Prostate. 2012 Feb; 72(3):301-6.
    View in: PubMed
    Score: 0.031
  110. Genome-wide association study of prostate cancer mortality. Cancer Epidemiol Biomarkers Prev. 2010 Nov; 19(11):2869-76.
    View in: PubMed
    Score: 0.029
  111. Fatty acid synthase polymorphisms, tumor expression, body mass index, prostate cancer risk, and survival. J Clin Oncol. 2010 Sep 01; 28(25):3958-64.
    View in: PubMed
    Score: 0.029
  112. A comprehensive analysis of common IGF1, IGFBP1 and IGFBP3 genetic variation with prospective IGF-I and IGFBP-3 blood levels and prostate cancer risk among Caucasians. Hum Mol Genet. 2010 Aug 01; 19(15):3089-101.
    View in: PubMed
    Score: 0.029
  113. Overexpression of fatty acid synthase is associated with palmitoylation of Wnt1 and cytoplasmic stabilization of beta-catenin in prostate cancer. Lab Invest. 2008 Dec; 88(12):1340-8.
    View in: PubMed
    Score: 0.025
  114. Prediagnostic body-mass index, plasma C-peptide concentration, and prostate cancer-specific mortality in men with prostate cancer: a long-term survival analysis. Lancet Oncol. 2008 Nov; 9(11):1039-47.
    View in: PubMed
    Score: 0.025
  115. A prospective study of plasma vitamin D metabolites, vitamin D receptor polymorphisms, and prostate cancer. PLoS Med. 2007 Mar; 4(3):e103.
    View in: PubMed
    Score: 0.023
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.